REFERENCES
1. Bansal MB, Patton H, Morgan TR, Carr RM, Dranoff JA, Allen AM. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance. Hepatology. 2026;83:1326-40.
2. Sanyal AJ, Newsome PN, Kliers I, et al. ; ESSENCE Study Group. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392:2089-99.
3. Harrison SA, Bedossa P, Guy CD, et al. ; MAESTRO-NASH Investigators. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497-509.
4. Schnell O, Agarwal A, Azizi M, et al. CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum. Cardiovasc Diabetol. 2026;25:142.
6. Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73:691-702.
7. Meyhöfer SM, Cariou B, Cercato C, et al. ; SELECT Trial Investigators. Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial. Nat Med. 2026;32:1686-93.
8. Newsome PN, Ambery P. Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver. J Hepatol. 2023;79:1557-65.
9. Chen VL, Morgan TR, Rotman Y, et al. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance. Hepatology. 2025;81:312-20.
10. Tacke F. Updates on EASL-EASD-EASO guidance for MASH-targeted pharmacotherapy. In: EASL 2026 Congress (European Association for the Study of the Liver); 2026 May 27-30; EASL; 2026. Available from https://pag.virtual-meeting.org/easl/easl2026/en-GB/pag/session/104319. [accessed 26 August 2026].
11. Wang H, Ma Q, Chen Y, Luo L, Ye J, Zhong B. Optimized strategy among diet, exercise, and pharmacological interventions for nonalcoholic fatty liver disease: a network meta-analysis of randomized controlled trials. Obes Rev. 2024;25:e13727.
12. Han X, Ai X, Sun Y, Chen S, Zhao X, You H. Comparative efficacy of pharmacologic therapies for MASLD in improving fibrosis: systematic review and network meta-analysis. Eur J Gastroenterol Hepatol. 2026;38:407-15.
13. Sanyal AJ, Van Natta ML, Clark J, et al. ; NASH Clinical Research Network (CRN). Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021;385:1559-69.
14. Wang L, Berger NA, Kaelber DC, Xu R. Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes. Gastroenterology. 2024;167:689-703.
15. Pearson SD, Whaley CM, Emond SK. Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US. J Comp Eff Res. 2025;14:e250083.
16. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335-47.
17. Loomba R, Hartman ML, Lawitz EJ, et al. ; SYNERGY-NASH Investigators. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391:299-310.
18. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30:2037-48.
19. Sanyal AJ, Bedossa P, Fraessdorf M, et al. ; 1404-0043 Trial Investigators. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391:311-9.
20. Kaplan LM, Startseva E, le Roux CW, et al. ; SYNCHRONIZE-MASLD Investigators. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2026;32:2948-58.
21. Noureddin M, Harrison SA, Loomba R, et al. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet. 2025;406:2644-55.
22. Liu CH, Zeng QM, Kim W, et al. Sarcopenia and MASLD: novel insights and the future. Nat Rev Endocrinol. 2026;22:139-52.
23. Deanfield J, Lincoff AM, Kahn SE, et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet. 2025;406:2257-68.
